Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abatacept, sold under the brand name Orencia, is a medication used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody.
Abatacept is used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. In order for a T cell to be activated and produce an immune response, an antigen-presenting cell must present two signals to the T cell. One of those signals is the major histocompatibility complex (MHC), combined with the antigen, and the other signal is the CD80 or CD86 molecule. Abatacept binds to the CD80 and CD86 molecule, and prevents the second signal. Without the second signal, the T cell can’t be activated. It also used to treat psoriatic arthritis and juvenile idiopathic arthritis.
| Products Name (INN Index) | Pre-Made Abatacept Biosimilar, Fusion Protein targeting CTLA4/CTLA-4 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 |
|---|---|
| INN Name | abatacept |
| Target | CTLA4 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [CTLA4 (cytotoxic T- lymphocyte- associated protein 4, CD152)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [CTLA4 (cytotoxic T- lymphocyte- associated protein 4, CD152)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Bristol-Myers Squibb (Princeton NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ctla-4 |
| Package |
